NCT07746518尚未招募3 期
A Multi-center, Double-blind, Randomized, Active-controlled, Parallel-group, Phase III Clinical Trial and Open-label Extension Study to Evaluate the Efficacy and Safety of DWP14012 for Maintenance Therapy in Patients With Healed Erosive Esophagitis
Daewoong Pharmaceutical Co. LTD.0 个研究点目标入组 420 人开始时间: 2026年9月1日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 420
- 主要终点
- Proportion (%) of subjects who maintain endoscopic remission* up to Week 24, as assessed by an independent central reader, after administration of the IP
研究概览
简要总结
A Multi-center, Double-blind, Randomized, Active-controlled, Parallel-group, Phase III Clinical Trial and Open-label Extension Study to Evaluate the Efficacy and Safety of DWP14012 for Maintenance Therapy in Patients with Healed Erosive Esophagitis
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
盲法说明
Part 1 (Double-blind Treatment Period) Multi-center, double-blind, randomized, active-controlled, parallel-group, Phase III clinical trial Part 2 (Open-label Extension Period) Open-label
入排标准
- 年龄范围
- 19 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adult men and women aged 19 to 75 years at the time of written informed consent
- •Diagnosed with EE on an upper gastrointestinal endoscopy prior to the initiation of standard therapy
- •Healing of EE confirmed by upper gastrointestinal endoscopy performed prior to Visit 2 (Randomization), defined as the absence of mucosal breaks according to the LA Grade classification, after completion of standard therapy
- •Able to understand the information provided and complete the questionnaire
- •Has voluntarily decided to participate in this clinical trial and has provided written informed consent
排除标准
- •Presence of heartburn or acid regurgitation within 7 days prior to Visit 2 (Randomization)
- •On screening upper gastrointestinal endoscopy, presence of Barrett's esophagus (>3 cm), esophageal varices, esophageal stricture, ulcer-related stricture, active peptic ulcer, acute gastrointestinal bleeding, or malignancy
- •Patients with inflammatory bowel disease , irritable bowel syndrome, primary esophageal motility disorder, or pancreatitis
- •History of gastric acid secretion-inhibiting surgery or surgery on the stomach/esophagus (e.g., gastrectomy, endoscopic mucosal resection) or total small bowel resection
- •Presence of alarm symptoms suggestive of gastrointestinal malignancy
- •Patients with Zollinger-Ellison syndrome
- •Patients with eosinophilic esophagitis
- •Subjects with diseases of the liver, kidney, nervous system, respiratory system, endocrine system, hematologic/oncologic system, cardiovascular system, or urinary system that, in the investigator's judgment, render them unsuitable for participation in this clinical trial
- •Subjects with a history of malignancy within the past 5 years
- •Subjects with a history of clinically significant psychiatric disorders.
- •Subjects with a history of drug or alcohol abuse within the past year.
- •Subjects diagnosed with Acquired Immune Deficiency Syndrome (AIDS).
- •Subjects who test positive for either Hepatitis B surface antigen (HBsAg) or Hepatitis C virus antibody (anti-HCV)
- •Subjects with hereditary disorders such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption
- •Subjects with hypersensitivity to any component of the IP or to benzimidazole-class drugs, or with a clinically significant history of hypersensitivity
- •Subjects who require continuous administration of any of the following medications(e.g. PPI, P-CAB, H2RAs, NSAIDs etc.) during the clinical trial period
- •Subjects who have received any other IP prior to administration of the IP
- •Subjects who meet any of the following criteria based on screening laboratory test results
- •Subjects who are unable to discontinue their current treatment for EE.
- •Subjects who have planned surgery requiring hospitalization that may affect gastric acid secretion or who require surgical treatment during the clinical trial period
- •Pregnant or breastfeeding women
- •Women of childbearing potential or men who do not agree to practice sexual abstinence or to use one of the acceptable methods of contraception during the clinical trial period and for 2 weeks after the last dose of the IP
- •Subjects unable to undergo upper gastrointestinal endoscopy
- •Subjects who, in the investigator's medical judgment, are considered unsuitable for participation in this clinical trial
研究组 & 干预措施
[Double-blind Treatment Period]Treatment group(DWP14012)
Experimental
Treatment group (DWP14012 20 mg group): 1 tablet of DWP14012 20 mg + 1 capsule of DWC202517 15 mg placebo for 24 weeks
干预措施: DWP14012 20mg (Drug)
[Double-blind Treatment Period]Treatment group(DWP14012)
Experimental
Treatment group (DWP14012 20 mg group): 1 tablet of DWP14012 20 mg + 1 capsule of DWC202517 15 mg placebo for 24 weeks
干预措施: DWC202517 15 mg placebo (Drug)
[Double-blind Treatment Period]Control group(DWC202517)
Active Comparator
1 tablet of DWP14012 20 mg placebo + 1 capsule of DWC202517 15 mg for 24weeks
干预措施: DWP14012 20 mg placebo (Drug)
[Double-blind Treatment Period]Control group(DWC202517)
Active Comparator
1 tablet of DWP14012 20 mg placebo + 1 capsule of DWC202517 15 mg for 24weeks
干预措施: DWC202517 15 mg (Drug)
[Open-label Extension Period]Maintenance group (DWP14012 20 mg/DWP14012 20 mg group)
Experimental
1 tablet of DWP14012 20 mg for 28weeks after Double-blind Treatment Period
干预措施: DWP14012 20mg (Drug)
[Open-label Extension Period]Switch group (DWC202517 15 mg/DWP14012 20 mg group)
Experimental
1 tablet of DWP14012 20 mg for 28weeks after Double-blind Treatment Period
干预措施: DWP14012 20mg (Drug)
结局指标
主要结局
Proportion (%) of subjects who maintain endoscopic remission* up to Week 24, as assessed by an independent central reader, after administration of the IP
时间窗: Week 24
次要结局
- Proportion (%) of subjects who maintain endoscopic remission* up to Week 24, as assessed by the investigator, after administration of the IP(Week 24)
- Proportion (%) of subjects who maintain endoscopic remission* up to Week 12, as assessed by an independent central reader and the investigator, after administration of the IP(Week 12)
研究者
相似试验
已完成
3 期
Clinical Trial to Evaluate the Efficacy and Safety of Combination Therapy of DW5421A/DW5421B Compared to Monotherapy of DW5421ANCT07444762Daewon Pharmaceutical Co., Ltd.184
招募中
3 期
Efficacy and Safety Evaluation of SMO1 in Patients With Retinal Vein Occlusive Macular EdemaRetinal Vein Occlusion With Macular EdemaNCT07708142SANGMYUNG innovation312
进行中（未招募）
3 期
A clinical trial to assess the efficacy and safety of Vilanterol, Glycopyrronium and Fluticasone furoate powder for inhalation as compared to Indacaterol, Glycopyrronium and Mometasone furoate powder for inhalation in patients with asthmaCTRI/2024/02/063046Zydus Healthcare Limited256
进行中（未招募）
3 期
Phase III clinical trial in the treatment of pressure ulcers also known as bedsores, decubitus ulcers and pressure injuries.CTRI/2024/05/068094Centaur Pharmaceuticals Pvt. Ltd232
已完成
3 期
Efficacy and Safety of THDB0206 Compared to Insulin Lispro Injection in Participants With Type 1 DiabetesType 1 DiabetesNCT07282054Tonghua Dongbao Pharmaceutical Co.,Ltd550